ACE2 and infection: A human monoclonal NAb, 1301B7, was isolated from a convalescent individual following Omicron infection in spring of 2023, using RBD-ACE2 fusion protein-based B cell isolation to enrich for antibodies targeting conserved ACE2-binding epitopes (16).